INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $417,150 | +72.9% | 22,500 | +3.1% | 0.00% | – |
Q2 2023 | $241,330 | -84.1% | 21,820 | -80.7% | 0.00% | -100.0% |
Q1 2023 | $1,521,900 | +249.1% | 113,321 | +322.3% | 0.00% | +200.0% |
Q1 2022 | $436,000 | -34.8% | 26,836 | -34.6% | 0.00% | 0.0% |
Q4 2021 | $669,000 | -59.1% | 41,028 | -62.7% | 0.00% | -85.7% |
Q3 2021 | $1,635,000 | -7.7% | 110,085 | +43.5% | 0.01% | -12.5% |
Q1 2021 | $1,772,000 | -2.3% | 76,723 | +4.5% | 0.01% | -20.0% |
Q4 2020 | $1,814,000 | +13.2% | 73,433 | +90.1% | 0.01% | 0.0% |
Q3 2020 | $1,602,000 | +5.3% | 38,628 | +186.9% | 0.01% | -86.3% |
Q1 2017 | $1,521,000 | -86.3% | 13,463 | -86.8% | 0.07% | 0.0% |
Q4 2016 | $11,121,000 | +85.3% | 102,360 | +180.7% | 0.07% | +69.8% |
Q3 2016 | $6,002,000 | -61.5% | 36,468 | -66.6% | 0.04% | -67.2% |
Q2 2016 | $15,570,000 | +3607.1% | 109,127 | +3241.3% | 0.13% | +3175.0% |
Q1 2016 | $420,000 | -67.9% | 3,266 | -58.7% | 0.00% | -75.0% |
Q3 2015 | $1,310,000 | +452.7% | 7,900 | +690.0% | 0.02% | +433.3% |
Q2 2014 | $237,000 | – | 1,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
CM Management, LLC | 45,000 | $668,000 | 0.50% |
EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |